Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

Not yet recruitingOBSERVATIONAL
Enrollment

594

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Type 2 Diabetes
Interventions
DRUG

Cofrogliptin add to insulin

Patients will be treated with commercially available cofrogliptin according to routine clinical practice at the discretion of the treating physician.

DRUG

Linagliptin add to insulin

Patients will be treated with commercially available linagliptin according to routine clinical practice at the discretion of the treating physician.

Trial Locations (7)

Unknown

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou

Affiliated Hospital of Hebei University, Baoding

Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing

the First Medical Center of Chinese PLA General Hospital, Beijing

Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai

Shanghai Changzheng Hospital, Shanghai

Xi'an International Medical Center Hospital, Xi'an

All Listed Sponsors
lead

Yanbing Li

OTHER